New algorithms designed to improve the diagnosis of certain forms of breast cancer have been launched and are currently available to patients and providers.
According to a release from the manufacturer, the uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis are designed to help determine the best treatment options for these patients. The two algorithms can help providers determine whether tumors are positive for the HER2 biomarker and help pathologists determine HER2 gene amplification, respectively. Thomas Schinecker, CEO of Roche Diagnostics, noted in the release that 15 to 20% of women diagnosed with breast cancer are HER2 positive. As a result, he said quick and accurate diagnosis of the condition is “critical.”
The release noted that the two algorithms were validated on the company’s VENTANA HER2 (4B5) assay and VENTANA HER2 Dual ISH DNA Probe Cocktail and are integrated into the company’s uPath software.